Lucia Masarova

Lucia Masarova

MD
The University of Texas MD Anderson Cancer Center
Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy 13:31
Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy
Aaron Gerds et al. • 12 Dec 2022
Assessing & improving the symptoms of patients with MPNs 2:12
Assessing & improving the symptoms of patients with MPNs
Lucia Masarova • 10 Dec 2022
Novel therapeutics in essential thrombocythemia 0:35
Novel therapeutics in essential thrombocythemia
Lucia Masarova • 10 Dec 2022
The need for disease-modifying agents in PV to prevent disease progression 1:25
The need for disease-modifying agents in PV to prevent disease progression
Lucia Masarova • 28 Sep 2022
Promising agents under investigation in polycythemia vera 1:04
Promising agents under investigation in polycythemia vera
Lucia Masarova • 28 Sep 2022
Hot topics in MPNs: disease-modifying drugs, sequencing JAK inhibitors and management of BP-MPNs 2:42
Hot topics in MPNs: disease-modifying drugs, sequencing JAK inhibitors and management of BP-MPNs
Lucia Masarova • 28 Sep 2022
The current treatment algorithm for polycythemia vera 3:07
The current treatment algorithm for polycythemia vera
Lucia Masarova • 28 Sep 2022
The characteristics of patients with myelofibrosis taking ruxolitinib for 3 or more years 1:38
The characteristics of patients with myelofibrosis taking ruxolitinib for 3 or more years
Lucia Masarova • 28 Sep 2022
An insight into how novel agents are influencing survival outcomes in patients with MF 3:54
An insight into how novel agents are influencing survival outcomes in patients with MF
Lucia Masarova • 26 Aug 2022
The importance of studying patient-reported outcomes in MPNs 1:46
The importance of studying patient-reported outcomes in MPNs
Lucia Masarova • 26 Aug 2022
Treating and managing blast-phase MPNs: a major unmet need 2:39
Treating and managing blast-phase MPNs: a major unmet need
Lucia Masarova • 26 Aug 2022
BET inhibition as a novel targeted therapy for myelofibrosis 4:26
BET inhibition as a novel targeted therapy for myelofibrosis
Lucia Masarova • 26 Aug 2022
Exciting updates in MF: novel targets and agents 1:04
Exciting updates in MF: novel targets and agents
Lucia Masarova • 26 Aug 2022
Targeted therapies in combination with ruxolitinib 8:45
Targeted therapies in combination with ruxolitinib
Lucia Masarova • 21 Aug 2020
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era 8:08
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era
Lucia Masarova • 21 Aug 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals